Areas of expertise: Clinical Development; Precision oncology; Preclinical-to-clinical stage transition of investigational targeted anticancer compound development; Creation and clinical validation of companion diagnostics in oncology; Molecular biology; Clinical validation of non-invasive device technology for the assessment of cardiovascular health.
Dr. Lenehan is a uniquely qualified physician-scientist and senior executive with broad experience in molecular biology, oncology and cardiovascular biotechnology, anticancer targeted pharmaceutical drug development, academia, and laboratory research who is engaged in and can effectively view translational medicine from scientific, clinical, and business perspectives. He is a critical thinker and skilled communicator who is particularly adept at conveying cutting edge advances in cancer genomics, emerging anticancer therapies, and cardiovascular risk assessment to his colleagues, outside investigators, and consultancy clients. A proven leader and effective manager, Peter is well versed in Phase I, II, and III clinical trial design/conduction and international regulatory strategies, including those for FDA’s IND, NDA, Pre-Sub, 510(k), and De Novo submissions, and EU’s medical device directives, including CE Mark.
Peter received his MD and PhD from the State University of New York Downstate Medical Center, Brooklyn, NY, having conducted his doctoral research in complement-dependent cytotoxicity in human leukemia, in part, in the Laboratory of Complement and Effector Biology at Memorial Sloan-Kettering Cancer Center, New York, NY. After completing an Internal Medicine residency at Thomas Jefferson University in Philadelphia and a Hematology/Oncology Fellowship at the University of Maryland Cancer Center in Baltimore, he joined the faculty of the University of Maryland, Baltimore. There, he continued his leukemia research, now aimed at defining the biochemical mechanisms of non-P-glycoprotein mediated multidrug resistance.
Subsequently, Dr. Lenehan spent 12 years at Pfizer Global Research & Development (legacy Warner-Lambert/Parke-Davis) in Ann Arbor, MI, where he led multiple international teams in the early phase clinical development of numerous investigational anticancer compounds, including a radiosensitizer and multiple targeted kinase inhibitors. More recently, Peter was Chief Medical Officer of Everist Genomics, Inc (aka Everist Health), focusing on the development of companion diagnostics in oncology and non-invasive device technology for the assessment of cardiovascular health.
He has published more than 50 manuscripts and abstracts and is co-inventor on 3 US patents.